News for Healthier Living

AOB Pharma Receives European Medicines Agency (EMA) Positive Decision on the Pediatric Investigation Plan (PIP), Supporting Future Development of B244 for the Treatment of Mild to Moderate Atopic Derm

B244, a first-in-class topical live biotherapeutic product, is currently planned for global Phase 3 development in mild to moderate atopic dermatitis and pruritus.

December 2, 2025


December 2 2025

December 1 2025

November 30 2025

November 29 2025

November 28 2025

November 27 2025

November 26 2025

November 25 2025

November 24 2025

November 23 2025

November 22 2025

November 21 2025

November 20 2025

November 19 2025

November 18 2025